COMPETITION: WIN (One of Twelve) AliveCor ECG mobile devices RRP £79!

NICE says ‘Yes’ to new heart failure medicine, Entresto™ (sacubitril/valsartan), in final recommendation * NICE recognises Entresto sacubitril valsartan as an innovative and cost-effective treatment in the management of symptomatic chronic heart failure with reduced ejection fraction * Heart failure affects around 550,000 people in the UK and has a poor prognosis for many patients, […]

NICE Publish Final Appraisal Determination for Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction National Institute for Health and Care Excellence (NICE) Recommendations in Final Appraisal Determination for Sacubitril valsartan Recommendations 1.1 Sacubitril valsartan is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction, only in people:  […]

Novartis’ new heart failure medicine, Entresto™, sacubitril valsartan accepted for use in Scotland by the Scottish Medicines Consortium  SMC recognised sacubitril valsartan represents a new therapeutic option for adult patients with symptomatic chronic heart failure with reduced ejection fraction1and may be used instead of the current gold standard treatment for the condition  Heart […]